Mark Weinsten
About Mark Weinsten
Appointed as a Class II director of GoHealth, Inc. on August 19, 2025; term runs to the 2028 annual meeting. Currently a Managing Director in BRG Corporate Finance, where he develops restructuring strategies, negotiates strategic transactions, and implements revenue and liquidity improvement programs. No age or education disclosed in company filings; independence status not explicitly stated by the Board.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BRG Corporate Finance | Managing Director | Not disclosed | Restructuring strategy, transactions, revenue/liquidity programs |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| BRG Corporate Finance | Managing Director | Not disclosed | Corporate finance and restructuring leadership |
Board Governance
- Appointment and classification: Class II director effective August 19, 2025; nominated as a Centerbridge designee under the 2020 Stockholders Agreement.
- Committee assignments: None disclosed for Weinsten at appointment; concurrently appointed director Bao Truong joined the Transformation, Compensation, and Nominating & Corporate Governance Committees.
- Controlled company: GOCO is a “controlled company” under Nasdaq rules due to Centerbridge and NVX Holdings controlling >50% voting power; has elected certain governance exemptions (e.g., committees not fully independent).
- Board structure and leadership: Co-Chairmen roles (founders) and lead independent director framework; regular executive sessions at least four times per year.
- Independence: Board independence determinations listed in the 2025 proxy do not include Weinsten (appointed after proxy date); independence for Centerbridge-affiliated directors has historically been recognized if they meet Nasdaq criteria, but Weinsten’s independence was not disclosed at appointment.
Fixed Compensation
| Component | Amount | Terms | Notes |
|---|---|---|---|
| Cash retainer | $25,000 per month | Pro-rated for first partial month | Board appointment terms (implies $300,000 annualized) |
| Expense reimbursement | Not quantified | Standard | Reimbursable for Board service expenses |
Benchmark vs. policy: Standard non-employee director annual cash retainer was $150,000 in 2024–2025; chairs/lead director also receive equity grants with higher values. Weinsten’s monthly retainer materially exceeds the standard retainer level.
Performance Compensation
| Award Type | Grant Date | Shares/Units | Vesting | Performance Metrics |
|---|---|---|---|---|
| RSUs (directors) – policy reference | Annual | $150,000 value for non-chairs; $250,000 for chairs/lead director | Quarterly vesting across 4 installments | N/A (time-based) |
| Weinsten awards | N/A disclosed | N/A | N/A | N/A |
No equity grants for Weinsten were disclosed at appointment; policy provides RSUs for non-employee directors, but Centerbridge-employed nominees historically receive no compensation. Weinsten is a Centerbridge designee but not disclosed as a Centerbridge employee; equity award treatment remains undisclosed.
Other Directorships & Interlocks
| Entity | Relationship | Governance Note |
|---|---|---|
| Centerbridge | Designee on GOCO Board | Centerbridge holds significant voting power and designation rights under the Stockholders Agreement. |
| NVX Holdings (Founders) | Significant holder | Combined with Centerbridge creates controlled company status. |
Expertise & Qualifications
- Restructuring, corporate finance, and liquidity improvement expertise (BRG Corporate Finance).
- Expected to contribute to debt/credit actions and operational restructuring, relevant given GOCO’s credit amendments and lender oversight in 2025.
Equity Ownership
| Metric | As of | Value/Count | Notes |
|---|---|---|---|
| Total beneficial ownership | Sept 3, 2025 (Form 3) | 0 shares | Initial beneficial ownership reported as none. |
| Ownership % of outstanding | Sept 3, 2025 | 0% | Based on 0 shares. |
| Vested vs. unvested | Sept 3, 2025 | None disclosed | No derivative/non-derivative holdings reported. |
| Pledging/Hedging | Policy level | Prohibited under Insider Trading Policy | Company policy bars hedging/pledging by directors. |
Insider Trades
| Date | Form | Non-Derivative Holdings | Derivative Holdings | Remarks |
|---|---|---|---|---|
| Sept 3, 2025 | Form 3 | 0 | N/A | Filed late due to EDGAR code delays; standard POA filed. |
Governance Assessment
-
Positives:
- Restructuring and transaction expertise aligns with 2025 credit and governance actions (superpriority credit, roll-up, transformation committee).
- Addition complements lender-designee oversight while two prior Centerbridge nominees resigned (board refresh).
-
Concerns and potential red flags:
- Compensation structure: $25,000/month cash retainer exceeds standard director cash retainer ($150,000/year), with no disclosed equity grant at appointment; heavier cash mix reduces at-risk alignment versus policy norms.
- Ownership alignment: Form 3 shows no beneficial ownership; no RSUs disclosed; limited skin-in-the-game signal at appointment.
- Affiliation: Centerbridge designee status in a controlled company with extensive designation rights may constrain board independence perceptions and heighten investor concern about potential influence and related-party sensitivities, albeit no Weinsten-specific related-party transactions disclosed.
- Committee engagement: No committee assignments disclosed for Weinsten at appointment, while co-appointee Truong immediately joined key committees (Compensation, Nominating).
-
Directional implications for investors:
- Expect focus on credit structure and operational improvement; monitor for equity grant disclosures to improve alignment, committee assignments to gauge engagement, and independence designation in future filings.
- Keep attention on controlled company exemptions and Transformation Committee activity for governance effectiveness signals.
Note: No say-on-pay or attendance data exists for Weinsten given mid-2025 appointment; 2024 board attendance exceeded 75% for then-serving directors, and executive sessions are held regularly.